Latest hormonal therapy Stories
Results presented at American Association of Cancer Research Annual Meeting 2015, Philadelphia, April 18-22 PHILADELPHIA, April 22, 2015 /PRNewswire/ -- Researchers at the Cancer Research
Women’s Excellence, now affiliated with Beaumont Hospital, offers comprehensive menopause treatment. Birmingham, Lake Orion, Clarkston, Metamora, MI.
LONDON, March 17, 2015 /PRNewswire/ -- Executive Summary--The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy,
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ -- [[CENTER] ]http://www.abmrg.com/Global-Oncology-Market---Trends-Forecast-and-Pipeline-Analysis.html
A breast cancer therapy that blocks estrogen synthesis to activate cancer-killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth.
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity.
Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies.
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy.
A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally: that the breast cancer drug tamoxifen is toxic to cells of the brain and central nervous system, producing mental fogginess similar to "chemo brain."
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.